Prognostic performance of pancreatic stone protein in critically ill patients with sepsis

Biomark Med. 2019 Dec;13(17):1469-1480. doi: 10.2217/bmm-2019-0174. Epub 2019 Oct 17.


Aim: To assess the prognostic value for 28-day mortality of PSP in critically ill patients with sepsis. Material & methods: 122 consecutive patients with sepsis were enrolled in this study. Blood samples were collected on admission and day 2. Results: On admission, the combination of PSP and lactate achieved an area under the receiver operating characteristic (AUC-ROC) of 0.796, similar to sequential organ failure assessment score alone (AUC-ROC: 0.826). On day 2, PSP was the biomarker with the highest performance (AUC-ROC: 0.844), although lower (p = 0.041) than sequential organ failure assessment score (AUC-ROC: 0.923). Conclusion: The combination of PSP and lactate and PSP alone, on day 2, have a good performance for prognosis of 28-day mortality and could help to identify patients who may benefit most from tailored intensive care unit management.

Keywords: 28-day mortality; C-reactive protein; SOFA score; lactate; pancreatic stone protein; procalcitonin; prognosis; sepsis; septic shock; serial biomarker measurements.

Publication types

  • Observational Study

MeSH terms

  • Aged
  • Biomarkers / blood
  • Critical Illness / mortality
  • Female
  • Humans
  • Lactic Acid / blood
  • Lithostathine / blood*
  • Male
  • Middle Aged
  • Organ Dysfunction Scores
  • Prognosis
  • Prospective Studies
  • ROC Curve
  • Sepsis / blood*
  • Sepsis / diagnosis
  • Sepsis / mortality


  • Biomarkers
  • Lithostathine
  • Lactic Acid